SNDX — Syndax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $1.25bn
- $172.35m
Syndax Pharmaceuticals Inc expected to post a loss of 98 cents a share - Earnings Preview
Brief: Syndax Announces Completion Of Enrollment In Augment-101 Pivotal Trial
Brief: Syndax Announces FDA Priority Review Of NDA For Revumenib
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Syndax Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Syndax Pharmaceuticals Files For Mixed Shelf- SEC Filing
Brief: Syndax Pharmaceuticals Q4 EPS USD -1
Syndax Pharmaceuticals Inc expected to post a loss of 99 cents a share - Earnings Preview
Brief: Syndax Pharmaceuticals Says Co Believes It Has Sufficient Cash Runway Through 2026
U.S. STOCKS ON THE MOVE-General Electric, BlackRock, Aadi Bioscience
Syndax Pharma falls on $200 mln stock offering
Brief: Syndax Announces Pricing Of $200 Million Public Offering Of Common Stock
Brief: Syndax Announces Proposed $150 Mln Public Offering Of Common Stock
Brief: Syndax Announces Positive Data For Revumenib In Patients With Acute Leukemias From BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
U.S. RESEARCH ROUNDUP-Bellring Brands, Deere & Co, Nvidia
Brief: Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation
Syndax Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Syndax Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview